2483-62-7

Basic information

• Product Name: 2-aminobutyric acid methyl ester
• Synonyms: 2-aminobutyric acid methyl ester;Methyl 2-aMinobutanoate
• CAS NO: 2483-62-7
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Mol File: 2483-62-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 127.8°Cat760mmHg
• Flash Point: 3.5°C
• Appearance: /
• Density: 0.987g/cm³
• Vapor Pressure: 11mmHg at 25°C
• Refractive Index: 1.427
• CAS DataBase Reference: 2-aminobutyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aminobutyric acid methyl ester(2483-62-7)
• EPA Substance Registry System: 2-aminobutyric acid methyl ester(2483-62-7)

Safety Data

• Hazardous Substances Data: 2483-62-7(Hazardous Substances Data)

Usage

General Description

2-Aminobutyric acid methyl ester, also known as β-amino-n-butyric acid methyl ester, is a chemical compound that belongs to the class of organic compounds known as alpha amino acid esters. It is derived from the amino acid GABA (gamma-aminobutyric acid) and is commonly used as a reagent in organic synthesis. 2-aminobutyric acid methyl ester is a white solid with a molecular weight of 133.17 g/mol. It is used in the production of pharmaceuticals, agrochemicals, and also as a building block in the synthesis of various organic compounds. The methyl ester group in this compound allows it to be easily incorporated into a variety of chemical reactions, making it a versatile and valuable chemical in the field of organic chemistry.

InChI:InChI=1/C5H11NO2/c1-3-4(6)5(7)8-2/h4H,3,6H2,1-2H3

Upstream product

• 22059-21-8 aminocyclopropane-1-carboxylic acid 
• 67-56-1 methanol 
• 1492-24-6 L-2-aminobutyric acid 
• 34306-42-8 Boc-Abu 
• 7324-11-0 (S)-2-amino-butanamide 
• 75266-39-6 methyl (S)-2-<<(benzyloxy)carbonyl>amino>-4-(methylsulfinyl)butanoate 
• 2491-18-1 (S)-methyl 2-amino-4-(methylthio)butanoate hydrochloride 
• 56762-93-7 methyl (S)-2-(benzyloxycarbonylamino)-4-methylmercaptobutanoate 
• 407578-43-2 (3S,6S)-3-isopropyl-6-ethylpiperazine-2,5-dione 
• 186581-53-3 diazomethane 
• 75266-40-9 N-benzyloxycarbonyl-L-α-vinylglycine methyl ester 
• 72784-43-1 methyl 1-aminocyclopropane-1-carboxylate 

Downstream Products

• 2623-91-8 (R)-2-aminobutyric acid 
• 1492-24-6 L-2-aminobutyric acid 
• 7652-88-2 α-Z-N^ε-BOC-L-Lysyl>-L-α-amino-buttersaeure-methylester 
• 102921-38-0 C₂₃H₂₁NO₈ 
• 96-20-8 2-aminobutanol 
• 7324-11-0 (S)-2-amino-butanamide 
• 1533422-35-3 methyl (S)-4-(4-methoxy-4-oxo-3-((trifluoromethyl)sulfonamido)butyl)benzoate 
• 53726-14-0 (S)-2-amino-butanamide hydrochloride 

Relevant articles and documents

Continuous-flow protocol for the synthesis of enantiomerically pure intermediates of anti epilepsy and anti tuberculosis active pharmaceutical ingredients

Continuous-flow production of chiral intermediates plays an important role in the development of building blocks for Active Pharmaceutical Ingredients (APIs), being α-amino acids and their derivatives widely applied as building blocks. In this work we developed two different strategies for the synthesis of intermediates used on the synthesis of levetiracetam/brivaracetam and ethambutol. The results obtained show that methionine methyl ester can be continuously converted to the desired ethambutol intermediate by RANEY Nickel dessulfurization/reduction strategy whereas levetiracetam/brivaracetam intermediates could be synthesized by both RANEY Nickel (without H2) and Pd/C-H2 approach or by photochemical desulfurization.

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC50 = 2579 nM, PLK1 IC50 = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.